New opioid receptor antagonist

Naltrexone-14-O-sulfate synthesis and pharmacology

Ferenc Zádor, Kornél Király, A. Váradi, Mihály Balogh, Ágnes Fehér, Dóra Kocsis, A. Erdei, Erzsébet Lackó, Z. Zádori, Sándor Hosztafi, B. Noszál, P. Riba, S. Benyhe, S. Fürst, M. Al-Khrasani

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Opioid antagonists, naloxone and naltrexone have long been used in clinical practice and research. In addition to their low selectivity, they easily pass through the blood-brain barrier. Quaternization of the amine group in these molecules, (e.g. methylnaltrexone) results in negligible CNS penetration. In addition, zwitterionic compounds have been reported to have limited CNS access. The current study, for the first time gives report on the synthesis and the in vitro [competition binding, G-protein activation, isolated mouse vas deferens (MVD) and mouse colon assay] pharmacology of the zwitterionic compound, naltrexone-14-O-sulfate. Naltrexone, naloxone, and its 14-O-sulfate analogue were used as reference compounds. In competition binding assays, naltrexone-14-O-sulfate showed lower affinity for µ, δ or κ opioid receptor than the parent molecule, naltrexone. However, the μ/κ opioid receptor selectivity ratio significantly improved, indicating better selectivity. Similar tendency was observed for naloxone-14-O-sulfate when compared to naloxone. Naltrexone-14-O-sulfate failed to activate [35S]GTPγS-binding but inhibit the activation evoked by opioid agonists (DAMGO, Ile5,6deltorphin II and U69593), similarly to the reference compounds. Schild plot constructed in MVD revealed that naltrexone-14-O-sulfate acts as a competitive antagonist. In mouse colon, naltrexone-14-O-sulfate antagonized the inhibitory effect of morphine with lower affinity compared to naltrexone and higher affinity when compared to naloxone or naloxone-14-O-sulfate. In vivo (mouse tail-flick test), subcutaneously injected naltrexone-14-O-sulfate antagonized morphine's antinociception in a dose-dependent manner, indicating it's CNS penetration, which was unexpected from such zwitter ionic structure. Future studies are needed to evaluate it's pharmacokinetic profile.

Original languageEnglish
Pages (from-to)111-121
Number of pages11
JournalEuropean Journal of Pharmacology
Volume809
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Naltrexone
Narcotic Antagonists
Sulfates
Pharmacology
Naloxone
Vas Deferens
Opioid Receptors
Morphine
Colon
Ala(2)-MePhe(4)-Gly(5)-enkephalin
Blood-Brain Barrier
GTP-Binding Proteins
Opioid Analgesics
Amines
Tail
Carrier Proteins
Pharmacokinetics

Keywords

  • Isolated organs
  • Mouse tail-flick assay
  • Naltrexone-14-O-sulfate
  • Opioid receptor binding

ASJC Scopus subject areas

  • Pharmacology

Cite this

New opioid receptor antagonist : Naltrexone-14-O-sulfate synthesis and pharmacology. / Zádor, Ferenc; Király, Kornél; Váradi, A.; Balogh, Mihály; Fehér, Ágnes; Kocsis, Dóra; Erdei, A.; Lackó, Erzsébet; Zádori, Z.; Hosztafi, Sándor; Noszál, B.; Riba, P.; Benyhe, S.; Fürst, S.; Al-Khrasani, M.

In: European Journal of Pharmacology, Vol. 809, 01.01.2017, p. 111-121.

Research output: Contribution to journalArticle

Zádor, Ferenc ; Király, Kornél ; Váradi, A. ; Balogh, Mihály ; Fehér, Ágnes ; Kocsis, Dóra ; Erdei, A. ; Lackó, Erzsébet ; Zádori, Z. ; Hosztafi, Sándor ; Noszál, B. ; Riba, P. ; Benyhe, S. ; Fürst, S. ; Al-Khrasani, M. / New opioid receptor antagonist : Naltrexone-14-O-sulfate synthesis and pharmacology. In: European Journal of Pharmacology. 2017 ; Vol. 809. pp. 111-121.
@article{bd64f5d3548c4adda92276eebdf0f826,
title = "New opioid receptor antagonist: Naltrexone-14-O-sulfate synthesis and pharmacology",
abstract = "Opioid antagonists, naloxone and naltrexone have long been used in clinical practice and research. In addition to their low selectivity, they easily pass through the blood-brain barrier. Quaternization of the amine group in these molecules, (e.g. methylnaltrexone) results in negligible CNS penetration. In addition, zwitterionic compounds have been reported to have limited CNS access. The current study, for the first time gives report on the synthesis and the in vitro [competition binding, G-protein activation, isolated mouse vas deferens (MVD) and mouse colon assay] pharmacology of the zwitterionic compound, naltrexone-14-O-sulfate. Naltrexone, naloxone, and its 14-O-sulfate analogue were used as reference compounds. In competition binding assays, naltrexone-14-O-sulfate showed lower affinity for µ, δ or κ opioid receptor than the parent molecule, naltrexone. However, the μ/κ opioid receptor selectivity ratio significantly improved, indicating better selectivity. Similar tendency was observed for naloxone-14-O-sulfate when compared to naloxone. Naltrexone-14-O-sulfate failed to activate [35S]GTPγS-binding but inhibit the activation evoked by opioid agonists (DAMGO, Ile5,6deltorphin II and U69593), similarly to the reference compounds. Schild plot constructed in MVD revealed that naltrexone-14-O-sulfate acts as a competitive antagonist. In mouse colon, naltrexone-14-O-sulfate antagonized the inhibitory effect of morphine with lower affinity compared to naltrexone and higher affinity when compared to naloxone or naloxone-14-O-sulfate. In vivo (mouse tail-flick test), subcutaneously injected naltrexone-14-O-sulfate antagonized morphine's antinociception in a dose-dependent manner, indicating it's CNS penetration, which was unexpected from such zwitter ionic structure. Future studies are needed to evaluate it's pharmacokinetic profile.",
keywords = "Isolated organs, Mouse tail-flick assay, Naltrexone-14-O-sulfate, Opioid receptor binding",
author = "Ferenc Z{\'a}dor and Korn{\'e}l Kir{\'a}ly and A. V{\'a}radi and Mih{\'a}ly Balogh and {\'A}gnes Feh{\'e}r and D{\'o}ra Kocsis and A. Erdei and Erzs{\'e}bet Lack{\'o} and Z. Z{\'a}dori and S{\'a}ndor Hosztafi and B. Nosz{\'a}l and P. Riba and S. Benyhe and S. F{\"u}rst and M. Al-Khrasani",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.ejphar.2017.05.024",
language = "English",
volume = "809",
pages = "111--121",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - New opioid receptor antagonist

T2 - Naltrexone-14-O-sulfate synthesis and pharmacology

AU - Zádor, Ferenc

AU - Király, Kornél

AU - Váradi, A.

AU - Balogh, Mihály

AU - Fehér, Ágnes

AU - Kocsis, Dóra

AU - Erdei, A.

AU - Lackó, Erzsébet

AU - Zádori, Z.

AU - Hosztafi, Sándor

AU - Noszál, B.

AU - Riba, P.

AU - Benyhe, S.

AU - Fürst, S.

AU - Al-Khrasani, M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Opioid antagonists, naloxone and naltrexone have long been used in clinical practice and research. In addition to their low selectivity, they easily pass through the blood-brain barrier. Quaternization of the amine group in these molecules, (e.g. methylnaltrexone) results in negligible CNS penetration. In addition, zwitterionic compounds have been reported to have limited CNS access. The current study, for the first time gives report on the synthesis and the in vitro [competition binding, G-protein activation, isolated mouse vas deferens (MVD) and mouse colon assay] pharmacology of the zwitterionic compound, naltrexone-14-O-sulfate. Naltrexone, naloxone, and its 14-O-sulfate analogue were used as reference compounds. In competition binding assays, naltrexone-14-O-sulfate showed lower affinity for µ, δ or κ opioid receptor than the parent molecule, naltrexone. However, the μ/κ opioid receptor selectivity ratio significantly improved, indicating better selectivity. Similar tendency was observed for naloxone-14-O-sulfate when compared to naloxone. Naltrexone-14-O-sulfate failed to activate [35S]GTPγS-binding but inhibit the activation evoked by opioid agonists (DAMGO, Ile5,6deltorphin II and U69593), similarly to the reference compounds. Schild plot constructed in MVD revealed that naltrexone-14-O-sulfate acts as a competitive antagonist. In mouse colon, naltrexone-14-O-sulfate antagonized the inhibitory effect of morphine with lower affinity compared to naltrexone and higher affinity when compared to naloxone or naloxone-14-O-sulfate. In vivo (mouse tail-flick test), subcutaneously injected naltrexone-14-O-sulfate antagonized morphine's antinociception in a dose-dependent manner, indicating it's CNS penetration, which was unexpected from such zwitter ionic structure. Future studies are needed to evaluate it's pharmacokinetic profile.

AB - Opioid antagonists, naloxone and naltrexone have long been used in clinical practice and research. In addition to their low selectivity, they easily pass through the blood-brain barrier. Quaternization of the amine group in these molecules, (e.g. methylnaltrexone) results in negligible CNS penetration. In addition, zwitterionic compounds have been reported to have limited CNS access. The current study, for the first time gives report on the synthesis and the in vitro [competition binding, G-protein activation, isolated mouse vas deferens (MVD) and mouse colon assay] pharmacology of the zwitterionic compound, naltrexone-14-O-sulfate. Naltrexone, naloxone, and its 14-O-sulfate analogue were used as reference compounds. In competition binding assays, naltrexone-14-O-sulfate showed lower affinity for µ, δ or κ opioid receptor than the parent molecule, naltrexone. However, the μ/κ opioid receptor selectivity ratio significantly improved, indicating better selectivity. Similar tendency was observed for naloxone-14-O-sulfate when compared to naloxone. Naltrexone-14-O-sulfate failed to activate [35S]GTPγS-binding but inhibit the activation evoked by opioid agonists (DAMGO, Ile5,6deltorphin II and U69593), similarly to the reference compounds. Schild plot constructed in MVD revealed that naltrexone-14-O-sulfate acts as a competitive antagonist. In mouse colon, naltrexone-14-O-sulfate antagonized the inhibitory effect of morphine with lower affinity compared to naltrexone and higher affinity when compared to naloxone or naloxone-14-O-sulfate. In vivo (mouse tail-flick test), subcutaneously injected naltrexone-14-O-sulfate antagonized morphine's antinociception in a dose-dependent manner, indicating it's CNS penetration, which was unexpected from such zwitter ionic structure. Future studies are needed to evaluate it's pharmacokinetic profile.

KW - Isolated organs

KW - Mouse tail-flick assay

KW - Naltrexone-14-O-sulfate

KW - Opioid receptor binding

UR - http://www.scopus.com/inward/record.url?scp=85020107892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020107892&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2017.05.024

DO - 10.1016/j.ejphar.2017.05.024

M3 - Article

VL - 809

SP - 111

EP - 121

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -